Opioids in chronic noncancer pain: Have we reached a boiling point Yet?

Pain Physician

Volumn 17, Issue 1, 2014, Pages

  Manchikanti, Laxmaiah ^a,b   Atluri, Sairam ^c   Hansen, Hans ^d   Benyamin, Ramsin M ^e,f   Falco, Frank J E ^g,h   Helm, Standiford ⁱ   Kaye, Alan D ^j   Hirsch, Joshua A ^k  

^a PAIN MANAGEMENT CENTER OF PADUCAH   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c Tri State Spine Care Institute   (United States)

^d Pain Relief Centers   (United States)

^e MILLENNIUM PAIN CENTER   (United States)

^f UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^g Mid Atlantic Spine and Pain Physicians   (United States)

^h TEMPLE UNIVERSITY HOSPITAL   (United States)

ⁱ The Helm Center for Pain Management   (United States)

^j LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESICS, OPIOID; CHRONIC PAIN; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS;

EID: 84893149169     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Manchikanti L, Hirsch JA. The pains of chronic opioid usage [Spotlight]. AHRQ WebM&M [serial online]. September 2013.
2. Betses M, Brennan T. Abusive prescribing of controlled substances--a pharmacy view. N Engl J Med 2013; 369:989-991.
3. Inocencio TJ, Carroll NV, Read EJ, Holdford DA. The economic burden of opioid-related poisoning in the United States. Pain Med 2013 [Epub ahead of print].
4. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJE, Fellows F, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm II S, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2 Guidance. Pain Physician 2012; 15:S67-S116.
5. Centers for Disease Control and Prevention. Drug Overdose in the United States: Fact Sheet. http://www.cdc.gov/homeandrecreationalsafety/overdose/facts.htm
6. Kirschner N, Ginsburg J, Sulmasy LS. Prescription drug abuse: A policy position paper from the American College of Physicians. Ann Intern Med 2013 [Epub ahead of print].
7. CDC. Policy Impact: Prescription Painkiller Overdoses, November 2011. www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf
8. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. JAMA 2014; in submission.
9. US Burden of Disease Collaborators. The state of US health, 1999-2010: Burden of diseases, injuries, and risk factors. JAMA 2013; 310:591-608.
10. Manchikanti L, Whitfield E, Pallone F. Evolution of the National All Schedules Prescription Electronic Reporting Act (NASPER): A public law for balancing treatment of pain and drug abuse and diversion. Pain Physician 2005; 8:335-347.
11. Liu Y, Logan JE, Paulozzi LJ, Zhang K, Jones CM. Potential misuse and inappropriate prescription practices involving opioid analgesics. Am J Manag Care. 2013; 19:648-665.
12. Department of Health and Human Services, Centers for Medicare & Medicaid Services. 42 CFR Parts 416, 419, 476, 478, 480, and 495. Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Electronic Reporting Pilot; Inpatient Rehabilitation Facilities Quality Reporting Program; Revision to Quality Improvement Organization Regulations. CY 2013. Final Rule. November 15, 2012.
13. Zheng Z, Paterson C, Ledgerwood K, Hogg M, Arnold CA, Xue CC. Chaos to hope: A narrative of healing. Pain Med 2013; 14:1826-1838.
14. Manchikanti L, Hirsch JA. Lessons learned in the abuse of pain relief medication: A focus on health care costs. Expert Rev Neurother 2013; 13:527-544.
15. Drug & Alcohol Services South Australia. Opioid prescription in chronic pain conditions. Guidelines for South Australian general practitioners (GPs). 2008. Available at: http://www.dassa.sa.gov.au/webdata/resources/files/Opioid_prescription_chronic_pain_guidelines_for_SA_GPs.pdf.
16. Boulanger A, Clark AJ, Squire P, Cui E, Horbay GLA. Chronic pain in Canada: Have we improved our management of chronic noncancer pain? Pain Res Manag 2007; 12:39-47.
17. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician 2012; 15:ES191-ES203.
18. Shield KD, Ialomiteanu A, Fischer B, Rehm J. Assessing the prevalence of nonmedical prescription opioid use in the Canadian general adult population: Evidence of large variation depending on survey questions used. BMC Psychiatry 2013; 13:6.
19. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011; 195:280-284.
20. Casati A, Sedefov R, Pfeiffer-Gerschel T. Misuse of medicines in the European Union: A systematic review of the literature. Eur Addict Res 2012; 18:228-245.
21. Stafford N. At least 25% of elderly residents of German nursing homes are addicted to psychotropic drugs, report claims. BMJ 2010; 340:c2029.
22. Report of the International Narcotics Control Board for 2011. United Nations, New York, NY, USA (2012). www. unodc.org/documents/southasia/reports/2011_INCB_ANNUAL_REPORT_ english_PDF.pdf (Accessed 2 January 2014).
23. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2010, Vienna, Austria: Division for Policy Analysis and Public Affairs, United Nations Office on Drugs and Crime (UNODC) (2010). Report No. E.10XI.13. www. unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf
24. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2011, Vienna, Austria: United Nations Office on Drugs and Crime (2011). www.unodc.org/documents/data-andanalysis/WDR2011/World_Drug_Re_2011_ebook.pdf
25. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283:1710-1714.
26. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004; 28:176-188.
27. Federation of State Medical Boards of the US. Model guidelines for the use of controlled substances for the treatment of pain: A policy document of the Federation of State Medical Boards of the United States, Inc. Dallas, TX, USA (1998). www.medsch.wisc.edu/painpolicy/domestic/model.htm
28. Manchikanti L, Helm II S, Fellows B, Janata JW, Pampati V, Grider JS, Boswell MV. Opioid epidemic in the United States. Pain Physician 2012; 15:ES9-ES38.
29. Fauber J. Painkiller boom fueled by networking. J Sentinel February 18, 2012.
30. Federation of State Medical Boards. Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. July 2013. www.fsmb.org/pdf/pain_policy_ july2013.pdf
31. Field MJ, Lohr KN, eds. Clinical Practice Guidelines: Directions for a New Program. Institute of Medicine, Washington, DC, E8 National Academy Press, 1990.
32. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012; 13:715-724.
33. Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA 2000; 284:428-429.
34. Letter to Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, US FDA, from Physicians for Responsible Opioid Prescribing RE Docket No. FDA-2011-D-0771, Draft Blueprint for Prescriber Education for Long-Acting/Extended Release Opioid ClassWide Risk Evaluation and Mitigation Strategies. December 2, 2011. www.rxre-form.org/wp-content/uploads/2011/11/ARPO-Statement-on-FDADraft-Blue-print-112911.pdf.
35. Deyo RA, Smith DH, Johnson ES, Donovan M, Tillotson CJ, Yang X, Petrik AF, Dobscha SK. Opioids for back pain patients: Primary care prescribing patterns and use of services. J Am Board Fam Med 2011; 24:717-727.
36. Ensuring availability of controlled medications for the relief of pain and preventing diversion and abuse: Striking the right balance to achieve the optimal public health outcome. Discussion paper based on a scientific workshop. UNODC, Vienna, Austria, 18-19 January 2011.
37. Chou R, Huffman L. Guideline for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain: Evidence Review. American Pain Society, Glenview, IL, 2009.
38. Manchikanti L, Abdi S, Atluri S, Balog CC, Benyamin RM, Boswell MV, Brown KR, Bruel BM, Bryce DA, Burks PA, Burton AW, Calodney AK, Caraway DL, Cash KA, Christo PJ, Damron KS, Datta S, Deer TR, Diwan S, Eriator I, Falco FJE, Fellows F, Geffert S, Gharibo CG, Glaser SE, Grider JS, Hameed H, Hameed M, Hansen H, Harned ME, Hayek SM, Helm II S, Hirsch JA, Janata JW, Kaye AD, Kaye AM, Kloth DS, Koyyalagunta D, Lee M, Malla Y, Manchikanti KN, McManus CD, Pampati V, Parr AT, Pasupuleti R, Patel VB, Sehgal N, Silverman SM, Singh V, Smith HS, Snook LT, Solanki DR, Tracy DH, Vallejo R, Wargo BW. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I - Evidence assessment. Pain Physician 2012; 15:S1-S66.
39. Manchikanti L, Ailinani H, Koyyalagunta D, Datta S, Singh V, Eriator I, Sehgal N, Shah RV, Benyamin RM, Vallejo R, Fellows B, Christo PJ. A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician 2011; 14:91-121.
40. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, Schoelles KM. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; 1:CD006605.
41. Chung JW, Zeng Y, Wong TK. Drug therapy for the treatment of chronic nonspecific low back pain: Systematic review and meta-analysis. Pain Physician 2013; 16:E685-E704.
42. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic noncancer pain: Systematic review of efficacy and safety. Pain 2004; 112:372-380.
43. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ 2006; 174:1589-1594.
44. Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician 2011; 14:E133-E156.
45. Stein C, Reinecke H, Sorgatz H. Opioid use in chronic noncancer pain: Guidelines revisited. Curr Opin Anaesthesiol 2010; 23:598-601.
46. Von Korff M, Kolodny A, Deyo RA, Chou R. Long-term opioid therapy reconsidered. Ann Intern Med 2011; 155:325-328.
47. Reinecke H, Sorgatz H; German Society for the Study of Pain (DGSS). S3 guideline LONTS. Long-term administration of opioids for nontumor pain. Schmerz 2009; 23:440-447.
48. Sorgatz H, Maier C. Nothing is more damaging to a new truth than an old error: Conformity of new guidelines on opioid administration for chronic pain with the effect prognosis of the DGSS S3 guidelines LONTS (long-term administration of opioids for non-tumor pain). Schmerz 2010; 24:309-312.
49. Martell BA, O'Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA. Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction. Ann Intern Med 2007; 146:116-127.
50. Manchikanti L, Singh V, Caraway DL, Benyamin RM. Breakthrough pain in chronic non-cancer pain: Fact, fiction, or abuse. Pain Physician 2011; 14:E103-E117.
51. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145-161.
52. Okie S. A flood of opioids, a rising tide of deaths. New Engl J Med 2010; 363:1981-1985.
53. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. Pain 1986; 25:171-186.
54. Catan T, Perez E. A pain-drug champion has second thoughts. The Wall Street Journal December 17, 2012.
55. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349: 1943-1953.
56. Ballantyne JC. Opioid analgesia: Perspectives on right use and utility. Pain Physician 2007; 10:479-491.
57. Ballantyne JC, Sullivan MD. Why doctors prescribe opioids to known opioid abusers. N Engl J Med 2013; 368:484-485.
58. Ballantyne JC. Chronic opioid therapy and its utility in different populations. Pain 2012; 153;2303-2304.
59. IMS Institute for Healthcare Informatics. The Global use of Medicines: Outlook Through 2015, May 2011. www.imshealth.com/deployedfiles/ims/Global/Content/Insights/IMS%20Insti-tute%20for%20Healthcare%20Infor-matics/Global_Use_of_Medicines_Report.pdf
60. The American Academy of Pain Medicine, the American Pain Society. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society, 1996. http://opi.areastematicas.com/general -idades/OPIOIDES.DOLORCRONICO. pdf
61. Fauber J. MedPage Today/Milwaukee Journal Sentinel series triggers senate investigation. Medpage Today, May 9, 2012.
62. Meier B. Senate inquiry into painkiller makers' ties. New York Times, May 8, 2012. www.nytimes.com/2012/05/09/health/senate-panel-to-examine-narcotic-drug-makers-financial-ties.html?_ r=0.
63. Ornstein C, Weber T. American Pain Foundation shuts down as senators launch investigation of prescription narcotics. ProPublic, May 8, 2012. www. propublica.org/article/senate-panel-investigates-drug-company-ties-to-pain-groups.
64. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309:657-659.
65. Centers for Disease Control and Prevention. CDC grand rounds: Prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012; 61:10-13.
66. US Government Accountability Office: Report to Congressional Requesters. Prescription Pain Reliever Abuse. December 2011. www.gao.gov/assets/590/587301.pdf.
67. Unintentional Drug Poisoning in the United States. Centers for Disease Control and Prevention. July 2010. www.cdc.gov/homeandrecreationalsafety/pdf/poison-issue-brief.pdf.
68. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: How physicians can help control it. J Clin Psychiatry 2011; 72:589-592.
69. Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009; 15:556-562.
70. White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005; 11:469-479.
71. Edlund MJ, Martin BC, Fan MY, Braden JB, Devries A, Sullivan MD. An analysis of heavy utilizers of opioids for chronic noncancer pain in the TROUP study. J Pain Symptom Manage 2010; 40:279-289.
72. White JA, Tao X, Talreja M, Tower J, Bernacki E. The effect of opioid use on workers' compensation claim cost in the State of Michigan. J Occup Environ Med 2012; 54:948-953.
73. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613-2620.
74. Lanier WA. Prescription opioid overdose deaths Utah, 2008-2009. Presented at: 59th Annual Epidemic Intelligence Service Conference. Atlanta, GA, April 19-23, 2010.
75. Public law No: 109-60. H.R.1132 signed by President George W. Bush on 8/11/05. http://thomas.loc.gov/bss/d109/d109laws.html
76. Physicians for Responsible Opioid Prescribing (PROP). www.supportprop.org
77. Centers for Disease Control and Prevention. Law: Regulating Pain Clinics. www.cdc.gov/homeandrecreationalsafety/Poisoning/laws/pain_clinic.html
78. U.S. Food and Drug Administration. Statement of proposed hydrocodone reclassification from Janet Woodcock, MD, Director, Center for Drug Evaluation and Research. October 24, 2013. www.fda.gov/drugs/drugsafety/ucm372089.htm
79. U.S. Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and LongActing Opioids.www.fda.gov/drugs/drugsafety/infor -mationbydrugclass/ucm163647.htm
80. U.S. Food and Drug Administration. FDA Acts to Reduce Harm from Opioid Drugs. www.fda.gov/forconsumers/consum -erupdates/ucm251830.htm
81. Kuehn BM. Prescription drug abuse rises globally. JAMA 2007; 297:1306.
82. Srivastava A, Kahan M, Jiwa A. Prescription opioid use and misuse: Piloting an educational strategy for rural primary care physicians. Can Fam Physician. 2012; 58:e210-e216.
83. Kuehn BM. FDA tightens indications for using long-acting and extended-release opioids to treat chronic pain. JAMA 2013; 310:1547-1548.
84. Raebel MA, Newcomer SR, Reifler LM, Boudreau D, Elliott TE, DeBar L, Ahmed A, Pawloski PA, Fisher D, Donahoo WT, Bayliss EA. Chronic use of opioid medications before and after bariatric surgery. JAMA 2013; 310:1369-1376.
85. Alford DP. Weighing in on opioids for chronic pain: the barriers to change. JAMA 2013; 310:1351-1352.
86. Saitz R, Cheng DM, Winter M, Kim TW, Meli SM, Allensworth-Davies D, LloydTravaglini CA, Samet JH. Chronic care management for dependence on alcohol and other drugs: The AHEAD randomized trial. JAMA 2013; 310:1156-1167.
87. Jha VM, Blum A. Abusive prescribing of controlled substances. N Engl J Med 2013; 369:2269-2270.
88. Starrels JL, Becker WC, Weiner MG, Li X, Heo M, Turner BJ. Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med 2011; 26:958-964.
89. Picetti E, Rossi I, Caspani ML. Management of opioid analgesic overdose. N Engl J Med 2012; 367:1372.
90. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367:187-189.
91. Manchikanti L, Cash KA, Malla Y, Pampati V, Fellows B. A prospective evaluation of psychotherapeutic and illicit drug use in patients presenting with chronic pain at the time of initial evaluation. Pain Physician 2013; 16:E1-E13.
92. Volkow ND, McLellan TA, Cotto JH. Characteristics of opioid prescriptions in 2009. JAMA 2011; 305:1299-1301.
93. Governale L. Outpatient prescription opioid utilization in the U.S., years 2000-2009. Drug Utilization Data Analysis Team Leader, Division of Epidemiology, Office of Surveillance and Epidemiology. Presentation for U.S. Food and Drug Administration, July 22, 2010.
94. SDI Vector One ®: National.
95. IMS Institute for Healthcare Informatics. The use of medicines in the United States: Review of 2011. April 2012. www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII_Medicines_in_U.S_Report_2011.pdf
96. Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, Chou R. Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2013 Nov 12. [Epub ahead of print]
97. Manchikanti L, Falco FJE, Hirsch JA. Letter to the editor: Re: Nuckols TK, et al. Opioid prescribing: A systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014; in submission.
98. Ballantyne JC, Stannard C. New addiction criteria: Diagnostic challenges persist in treating pain with opioids. Pain: Clinical Updates, December 2013.
99. Koeppe J, Lyda K, Armon C. Association between opioid use and health care utilization as measured by emergency room visits and hospitalizations among persons living with HIV. Clin J Pain 2013; 29:957-961.
100. National Opioids Use Guideline Group (NOUGG). Canadian guidelines for safe and effective use of opioids for chronic non-cancer pain, Executive Summary and Background, Version 4.5. April 30, 2010.